[go: up one dir, main page]

DE69924232D1 - Stabilisierte insulin-zubereitungen - Google Patents

Stabilisierte insulin-zubereitungen

Info

Publication number
DE69924232D1
DE69924232D1 DE69924232T DE69924232T DE69924232D1 DE 69924232 D1 DE69924232 D1 DE 69924232D1 DE 69924232 T DE69924232 T DE 69924232T DE 69924232 T DE69924232 T DE 69924232T DE 69924232 D1 DE69924232 D1 DE 69924232D1
Authority
DE
Germany
Prior art keywords
insulin preparations
stabilized insulin
glycylglycine
analogue
citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69924232T
Other languages
English (en)
Inventor
Peter Langballe
Elsebeth Norup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69924232D1 publication Critical patent/DE69924232D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69924232T 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen Expired - Lifetime DE69924232D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98610001 1998-01-09
PCT/DK1999/000006 WO1999034821A1 (en) 1998-01-09 1999-01-06 Stabilised insulin compositions

Publications (1)

Publication Number Publication Date
DE69924232D1 true DE69924232D1 (de) 2005-04-21

Family

ID=8235844

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69924232T Expired - Lifetime DE69924232D1 (de) 1998-01-09 1999-01-06 Stabilisierte insulin-zubereitungen

Country Status (7)

Country Link
US (1) US6174856B1 (de)
EP (1) EP1044016B1 (de)
JP (1) JP2002500196A (de)
AT (1) ATE290877T1 (de)
AU (1) AU1870099A (de)
DE (1) DE69924232D1 (de)
WO (1) WO1999034821A1 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4750643A1 (es) * 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
PT1146896E (pt) * 1999-01-26 2002-10-31 Lilly Co Eli Formulacoes monodispersas de analogo acilado e hexamerico insulina
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
US20030148924A1 (en) * 2002-07-09 2003-08-07 Tamar Tennenbaum Methods and pharmaceutical compositions of healing wounds
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
US20100129332A1 (en) * 2000-07-31 2010-05-27 Tamar Tennenbaum Methods and pharmaceutical compositions for healing wounds
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
WO2002009639A2 (en) * 2000-07-31 2002-02-07 Bar Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US20030158670A1 (en) * 2001-12-04 2003-08-21 Philip Hougaard Method of planning and performing stability studies
AU2003208316A1 (en) * 2002-03-13 2003-09-22 Novo Nordisk A/S Minimising body weight gain in insulin treatment
JP2005526126A (ja) * 2002-05-07 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20040126831A1 (en) * 2002-12-31 2004-07-01 Medtronic Minimed, Inc. Functionalization of immobilized proteins
BRPI0413276B8 (pt) * 2003-08-05 2021-05-25 Novo Nordisk As derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
CN101027318B (zh) * 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
EP2256130B1 (de) 2005-02-02 2013-09-25 Novo Nordisk A/S Neuartige Insulinderivate
AU2006286152B2 (en) 2005-08-29 2012-05-31 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
EP1991576B1 (de) * 2006-02-27 2010-09-29 Novo Nordisk A/S Insulinderivate
WO2007128817A2 (en) * 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
JP5269766B2 (ja) * 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US20100310542A1 (en) * 2007-07-30 2010-12-09 Healor Ltd. Pharmaceutical Compositions for treating wouds and related methods
CN101939023B (zh) * 2007-10-16 2016-08-03 百康有限公司 可经口给药的固体药物组合物及其方法
ES2543393T3 (es) * 2007-11-08 2015-08-18 Novo Nordisk A/S Derivado de insulina
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
EP2113564A1 (de) * 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
FR2932908B1 (fr) * 2008-06-24 2012-11-16 Arjowiggins Licensing Sas Structure comportant un filigrane ou pseudo-filigrane et un dispositif a microcircuit integre.
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
MX2011004357A (es) * 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
EP2391217A4 (de) 2009-01-28 2015-05-20 Smartcells Inc Synthetische konjugate und ihre verwendung
SG193837A1 (en) 2009-01-28 2013-10-30 Smartcells Inc Conjugate based systems for controlled drug delivery
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
SG177567A1 (en) * 2009-07-06 2012-02-28 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
WO2011049776A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically effective preparations of insulin
HUE038147T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland GLP-1 agonistát, inzulint és metionint tartalmazó gyógyászati készítmény
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
CN102724994A (zh) 2010-01-11 2012-10-10 希尔洛有限公司 用于治疗炎性疾病和病症的方法
US20120178675A1 (en) * 2010-07-07 2012-07-12 Biodel Inc. Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
CN107952065A (zh) 2012-11-13 2018-04-24 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
EP2925345B1 (de) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Methode zur herstellung von o-glycosyliertem carboxyterminus-peptid (ctp)-basiertem insulin und insulinanaloga
JP6111475B2 (ja) 2012-12-19 2017-04-12 ウォックハート リミテッド ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
RU2015130613A (ru) 2012-12-26 2017-01-31 Вокхардт Лимитед Фармацевтическая композиция
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
CN107530372A (zh) * 2015-02-25 2018-01-02 当斯生物制药有限公司 液体胰岛素制剂及与其相关的方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
CR20190522A (es) 2017-06-01 2020-01-15 Lilly Co Eli Composiciones de insulina de rápida acción
EP3727424A4 (de) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Konjugatbasierte systeme für kontrollierte insulinfreisetzung
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CA3173417A1 (en) 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
US20240374735A1 (en) 2020-11-19 2024-11-14 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
KR20250005573A (ko) 2022-05-18 2025-01-09 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 관련 인슐린 유사체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU550068B2 (en) 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
JP2628340B2 (ja) * 1988-05-14 1997-07-09 株式会社いかがく 血液中のインシュリン成分の安定方法
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
EP0705275B1 (de) * 1993-06-21 1999-02-03 Novo Nordisk A/S Asp-b28-insulinkristalle
CN1056618C (zh) * 1993-09-17 2000-09-20 诺沃挪第克公司 酰化的胰岛素和含有这种胰岛素的药物组合物
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
HU228094B1 (en) * 1996-06-20 2012-10-29 Novo Nordisk As Insulin preparations containing nacl

Also Published As

Publication number Publication date
EP1044016B1 (de) 2005-03-16
WO1999034821A1 (en) 1999-07-15
EP1044016A1 (de) 2000-10-18
ATE290877T1 (de) 2005-04-15
US6174856B1 (en) 2001-01-16
JP2002500196A (ja) 2002-01-08
AU1870099A (en) 1999-07-26

Similar Documents

Publication Publication Date Title
DE69924232D1 (de) Stabilisierte insulin-zubereitungen
DK1175149T3 (da) Desinficerende sammensætning baseret på H2O2, syrer og metaliioner
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
BR9911724A (pt) Ciclosporina que tem um perfil de atividade melhorado
HU9902655D0 (en) Pharmaceutical composition of hedgehog proteins and use thereof
IL127366A0 (en) Insulin preparations containing NaCl
NO20012994D0 (no) Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
NO20015471D0 (no) Arrangement og fremgangsmåte for innholdskontroll av dataobjekter, spesielt dataobjekter i MMS-meldinger
DE69927795D1 (en) Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus
NO20031860L (no) Kahalalid F
BRPI0209619B8 (pt) agente promotor de crescimento capilar
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
GB0027405D0 (en) Composition
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
NO20024760D0 (no) Stabil og effektiv myk, fast antiperspirant og/eller deodorant
MY128230A (en) Antifungal composition
DE60131085D1 (de) Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
RS50355B (sr) Formulacije eritropoietina sa više doza
MY138219A (en) Biologically active peptides
BR0317119A (pt) Agente antitumor, inibidor de proliferação celular, e, análogo de 3-fenil-cinolina
DE69813833D1 (de) 4-cyano-4-deformylsordarizin-derivate
DE69815355D1 (de) 4-cyano-4-deformylsordarinderivate
SE9502927D0 (sv) Solution containing IGF-I
DE69602208D1 (de) Stabilisierte pharmazeutische zusammensetzungen enthaltend dobutamine

Legal Events

Date Code Title Description
8332 No legal effect for de